Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen

S Y Jiang1, V C Jordan

  • 1Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison 53792.

Abstract

Insights

Estrogen receptor-negative breast cancer cells regained hormonal responsiveness after transfection with estrogen receptor (ER) genes. However, estradiol inhibited cell growth, suggesting a novel therapeutic strategy for ER-negative cancers.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Endocrinology

Background:

  • Estrogen receptor (ER)-positive breast cancer growth is hormone-dependent.
  • ER-negative breast cancers are unresponsive to hormonal therapies.
  • Developing therapeutic strategies for ER-negative breast cancer is crucial.

Purpose of the Study:

  • To determine if hormonal control over replication can be re-established in ER-negative cells.
  • To investigate the functionality of transfected wild-type and mutant ER in ER-negative cells.
  • To explore potential therapeutic approaches for ER-negative breast cancer.

Main Methods:

  • Transfection of ER-negative MDA-MB-231 cells with ER expression vectors.
  • Northern and Western blot analyses to detect ER and neomycin resistance (neo) mRNA and protein.
  • Enzyme immunoassay and ligand-binding assays to quantify ER levels.
  • Functional assays including reporter gene activation, progesterone receptor induction, DNA replication, and cell cycle kinetics analysis.

Main Results:

  • Transfected ER-negative cells expressed ER mRNA and protein.
  • Transfected ER (both wild-type and mutant) was functional, responding to 17 beta-estradiol (E2) and antiestrogen ICI 164,384.
  • E2 inhibited DNA replication in transfected cells, an effect blocked by ICI 164,384.

Conclusions:

  • Stable transfection of ER-negative breast cancer cells with ER genes restores hormonal responsiveness.
  • Estradiol inhibits, rather than stimulates, cell growth in these reactivated cells.
  • Reactivating ER in ER-negative breast cancer presents a potential novel therapeutic avenue.